Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

 
Press Releases
  Date Title View
Apr 13, 2005
OXiGENE Announces Presentations on Lead Vascular Targeting Agents at American Association of Cancer Research

Seven Poster Presentations on CA4P and OXi4503 at AACR WALTHAM, Mass.--(BUSINESS WIRE)--April 13, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) today announced the topics and schedules for seven poster presentations on OXiGENE compounds at the 96th Annual Meetin...

Mar 30, 2005
OXiGENE to Present at Lehman Brothers Eighth Annual Global HealthCare Conference: April 1st Presentation Available via Live Webcast

WALTHAM, Mass.--(BUSINESS WIRE)--March 30, 2005--OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN), a leading developer of biopharmaceutical compounds designed to target aberrant blood vessels within solid tumor cancers and ocular neovascular diseases, today announced that President and Chief Executive Officer Fred Driscoll will present at Lehman Brot...

Mar 25, 2005
OXiGENE, Inc. Adopts Stockholder Rights Plan

WALTHAM, Mass.--(BUSINESS WIRE)--March 25, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) announced today that its Board of Directors has adopted a Stockholder Rights Plan (the "Rights Plan") that is designed to strengthen the ability of the Board of Directors to protect OXiGENE's stockholders. The Rights Plan was not adopted in response to an...

Mar 4, 2005
OXiGENE to Present at 3rd International Symposium on Targeted Anticancer Therapies

WALTHAM, Mass.--(BUSINESS WIRE)--March 4, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a leading developer of biopharmaceutical compounds designed to target aberrant blood vessels within solid tumor cancers and ocular neovascular diseases, today announced that Chief Scientific Officer, Dai Chaplin, will present at the 3rd International Symp...

Mar 4, 2005
OXiGENE Announces Sale of $15 Million of Common Stock

WALTHAM, Mass.--(BUSINESS WIRE)--March 4, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) today announced that the Company will receive gross proceeds of $15 million from the sale of 3,336,117 shares of its common stock, pursuant to OXiGENE's effective shelf registration statement filed in October 2003. The shares are being sold to certain inst...

Mar 1, 2005
OXiGENE to Present at Wells Fargo Securities 2005 HealthCare Conference: March 2nd Presentation Available via Live Webcast

WALTHAM, Mass.--(BUSINESS WIRE)--March 1, 2005--OXiGENE, Inc. (NASDAQ:OXGN, XSSE:OXGN), a leading developer of biopharmaceutical compounds designed to target aberrant blood vessels within solid tumor cancers and ocular neovascular diseases, today announced that President and Chief Executive Officer Fred Driscoll will present at Wells Fargo Sec...

Feb 25, 2005
OXiGENE Reports Fourth-Quarter and Year-End 2004 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 25, 2005--Accomplishments in 2004: Initiated two new clinical oncology trials with CA4P; CA4P now studied in seven clinical oncology trials Initiated a Phase II trial of CA4P...

Feb 22, 2005
OXiGENE to Participate on Distinguished Anti-angiogenesis Panel at BIO CEO & Investor Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 22, 2005--OXiGENE Inc, (NASDAQ: OXGN, SSE: OXGN) today announced that Dai Chaplin, Chief Scientific Officer of OXiGENE, will participate in a focus session entitled "Starving Cancer" at the Biotechnology Industry Organization's CEO & Investor Conference on Thursday, February 24, 2005 9:30 AM. The confe...

Feb 18, 2005
OXiGENE to Present at Roth Capital Partners 17th Annual OC Conference: February 22nd Presentation Available via Live Webcast

WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 18, 2005--OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN), today announced that President and Chief Executive Officer Fred Driscoll will present at Roth Capital Partners 17th Annual OC Conference, at the St. Regis Monarch Beach Resort and Spa in Dana Point, California.. ...

Feb 14, 2005
OXiGENE's Lead Compound CA4P Enhances the Anti-Tumor Activity of Avastin in Pre-clinical Studies

Data Presented at International Symposium on Anti-Angiogenic Agents Conference in La JollaWALTHAM, Mass., Feb 14, 2005 (BUSINESS WIRE) -- OXiGENE, Inc. (Nasdaq: OXGN, XSSE: OXGN) announced today that Dietmar Siemann, Ph.D., chairman of its scientific advisory boar...

FirstPrevious
...
34
NextLast
= add release to Briefcase